Seok Won Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5329832/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. Cancer Research and Treatment, 2022, 54, 827-833.	3.0	2
2	Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors. Cancer Research and Treatment, 2022, 54, 834-841.	3.0	9
3	Impact of Skeletal Muscle Loss and Visceral Obesity Measured Using Serial CT on the Prognosis of Operable Breast Cancers in Asian Patients. Korean Journal of Radiology, 2022, 23, 159.	3.4	4
4	Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching. Breast Cancer Research and Treatment, 2022, 192, 101-112.	2.5	1
5	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Research and Treatment, 2022, , .	3.0	8
6	Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 749-758.	2.8	2
7	Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Research, 2022, 82, P1-08-07-P1-08-07.	0.9	0
8	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Research, 2022, 82, P3-13-08-P3-13-08.	0.9	0
9	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. Journal of Breast Cancer, 2022, 25, 94.	1.9	4
10	Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. European Journal of Surgical Oncology, 2021, 47, 232-239.	1.0	7
11	Changes in Korean National Healthcare Insurance Policy and Breast Cancer Surgery Trend in Korea. Journal of Korean Medical Science, 2021, 36, e194.	2.5	2
12	Effect of Poloxamer-Based Thermo-Sensitive Sol-Gel Agent on Upper Limb Dysfunction after Axillary Lymph Node Dissection: A Double-Blind Randomized Clinical Trial. Journal of Breast Cancer, 2021, 24, 367.	1.9	3
13	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2â^' Early Breast Cancer. Frontiers in Oncology, 2021, 11, 588728.	2.8	2
14	Abstract PS10-38: Real Would Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience. , 2021, , .		0
15	The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMarkâ,,¢) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial. BMC Surgery, 2021, 21, 134.	1.3	5
16	Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells. Oncology Reports, 2021, 45, .	2.6	17
17	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. Frontiers in Oncology, 2021, 11, 596364.	2.8	14
18	Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells. Molecules, 2021, 26, 3644.	3.8	7

#	Article	IF	CITATIONS
19	Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. Frontiers in Oncology, 2021, 11, 691277.	2.8	4
20	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Scientific Reports, 2021, 11, 14747.	3.3	1
21	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. Breast Cancer Research and Treatment, 2021, 189, 653-663.	2.5	10
22	Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?. BMC Cancer, 2021, 21, 88.	2.6	8
23	Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. Journal of Breast Cancer, 2021, 24, 75.	1.9	19
24	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Cancers, 2021, 13, 5260.	3.7	11
25	Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study. Journal of Clinical Medicine, 2021, 10, 4754.	2.4	0
26	Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. JAMA Surgery, 2020, 155, 1132.	4.3	27
27	ANK2 Hypermethylation in Canine Mammary Tumors and Human Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 8697.	4.1	11
28	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nature Communications, 2020, 11, 6175.	12.8	92
29	WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. Cytokine, 2020, 135, 155213.	3.2	9
30	Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	1.1	5
31	Serum Vitamin Levels and Their Relationships with Other Biomarkers in Korean Breast Cancer Patients. Nutrients, 2020, 12, 2831.	4.1	6
32	Impact of Serum Lipid on Breast Cancer Recurrence. Journal of Clinical Medicine, 2020, 9, 2846.	2.4	23
33	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184, 325-334.	2.5	18
34	Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 863.	2.8	9
35	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. Molecular Cancer Research, 2020, 18, 1315-1325.	3.4	8
36	Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Japanese Journal of Clinical Oncology, 2020, 50, 104-113.	1.3	2

#	Article	IF	CITATIONS
37	Aberrant Lymphatic Drainage in the Contralateral Axilla in Patients with Isolated Ipsilateral Breast Tumor Recurrence. Journal of Clinical Medicine, 2020, 9, 1192.	2.4	0
38	Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. Journal of Pathology and Translational Medicine, 2020, 54, 95-102.	1.1	19
39	Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study. Annals of Surgical Treatment and Research, 2020, 98, 215.	1.0	8
40	Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative node breast cancer?. Annals of Surgical Treatment and Research, 2020, 99, 251.	1.0	5
41	TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells. Oncology Reports, 2019, 41, 1075-1082.	2.6	7
42	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
43	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice, 2019, 17, 1.	1.5	13
44	Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients. Nutrients, 2019, 11, 37.	4.1	46
45	Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 176, 591-596.	2.5	25
46	Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. PLoS ONE, 2019, 14, e0212309.	2.5	18
47	Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. Annals of Surgical Treatment and Research, 2019, 96, 169.	1.0	22
48	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Research and Treatment, 2019, 173, 385-395.	2.5	15
49	A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning. European Journal of Surgical Oncology, 2019, 45, 134-140.	1.0	17
50	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Research and Treatment, 2019, 173, 255-266.	2.5	96
51	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. Breast Cancer Research and Treatment, 2019, 173, 189-199.	2.5	27
52	EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. Cellular Physiology and Biochemistry, 2019, 53, 805-819.	1.6	26
53	Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm. Journal of Breast Cancer, 2019, 22, 613.	1.9	18
54	Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 795-807.	1.6	47

#	Article	IF	CITATIONS
55	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer, 2018, 18, e1141-e1147.	2.4	24
56	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 2018, 9, 1725.	12.8	122
57	Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane. Clinical Breast Cancer, 2018, 18, e49-e54.	2.4	18
58	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. Translational Oncology, 2018, 11, 18-23.	3.7	26
59	Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer. World Journal of Surgery, 2018, 42, 1384-1390.	1.6	9
60	Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study. Journal of Breast Cancer, 2018, 21, 447.	1.9	2
61	Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis. Journal of Breast Cancer, 2018, 21, 433.	1.9	19
62	Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapyâ€ŧreated triple negative breast cancer. Kaohsiung Journal of Medical Sciences, 2018, 34, 663-672.	1.9	8
63	Only estrogen receptor "positive―is not enough to predict the prognosis of breast cancer. Breast Cancer Research and Treatment, 2018, 172, 627-636.	2.5	10
64	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Research and Treatment, 2018, 171, 737-745.	2.5	27
65	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. Journal of Breast Cancer, 2018, 21, 206.	1.9	8
66	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells. Journal of Breast Cancer, 2018, 21, 21.	1.9	19
67	Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy. Journal of Breast Cancer, 2018, 21, 91.	1.9	10
68	Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 173.	1.9	28
69	Verification of a Western Nomogram for Predicting Oncotype DXâ"¢ Recurrence Scores in Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 222.	1.9	4
70	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine, 2018, 50, 43-49.	5.3	56
71	Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype. Oncology, 2018, 95, 163-169.	1.9	31
72	Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis Journal of Clinical Oncology, 2018, 36, e12640-e12640.	1.6	0

#	Article	IF	CITATIONS
73	Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis. Clinical Breast Cancer, 2017, 17, 550-558.	2.4	18
74	Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society. Medical Oncology, 2017, 34, 118.	2.5	8
75	Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from â€`unknown significance' to â€`Likely pathogenic' based on clinical evidence in Korea. Breast, 2017, 33, 109-116.	2.2	16
76	Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2017, 166, 833-842.	2.5	20
77	Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case–Control Study. Clinical Breast Cancer, 2017, 17, 204-210.	2.4	24
78	Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2017, 161, 95-102.	2.5	28
79	Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. Clinical Breast Cancer, 2017, 17, e19-e29.	2.4	14
80	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 329-336.	1.1	12
81	Development of a Nomogram to Predict N2 or N3 Stage in T1–2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy. Journal of Breast Cancer, 2017, 20, 270.	1.9	12
82	Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry. Journal of Breast Cancer, 2017, 20, 297.	1.9	31
83	Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy. Journal of Breast Cancer, 2017, 20, 91.	1.9	6
84	Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study. Journal of Breast Cancer, 2017, 20, 74.	1.9	15
85	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget, 2017, 8, 50570-50581.	1.8	33
86	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. Oncotarget, 2017, 8, 86423-86434.	1.8	14
87	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget, 2017, 8, 100296-100311.	1.8	25
88	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. Journal of Breast Cancer, 2016, 19, 169.	1.9	11
89	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Research and Treatment, 2016, 48, 1338-1350.	3.0	56
90	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. Cancer Research and Treatment, 2016, 48, 1382-1388.	3.0	10

#	Article	IF	CITATIONS
91	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS ONE, 2016, 11, e0163254.	2.5	6
92	Frequency of <scp>MED</scp> 12 mutations in phyllodes tumors: Inverse correlation with histologic grade. Genes Chromosomes and Cancer, 2016, 55, 495-504.	2.8	24
93	The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Scientific Reports, 2016, 6, 31804.	3.3	44
94	Feasibility of Nippleâ€Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumorâ€Nipple Distance Less Than 2.0Âcm. World Journal of Surgery, 2016, 40, 2028-2035.	1.6	21
95	Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society. Breast Cancer Research and Treatment, 2016, 159, 489-498.	2.5	6
96	Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. Breast, 2016, 30, 111-117.	2.2	4
97	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer, 2016, 16, 138.	2.6	39
98	Limited Supraclavicular Radiation Field in Breast Cancer WithÂ≥ 10 Positive Axillary Lymph Nodes. Clinical Breast Cancer, 2016, 16, e15-e21.	2.4	1
99	Analysis of <i>BRIP1</i> Variants among Korean Patients with <i>BRCA1/2</i> Mutation-Negative High-Risk Breast Cancer. Cancer Research and Treatment, 2016, 48, 955-961.	3.0	8
100	Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	0
101	Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. Journal of Breast Cancer, 2015, 18, 22.	1.9	23
102	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	1.9	5
103	Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery. Journal of Breast Cancer, 2015, 18, 386.	1.9	13
104	Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS ONE, 2015, 10, e0124658.	2.5	27
105	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget, 2015, 6, 24499-24510.	1.8	7
106	Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. Surgery, 2015, 157, 518-525.	1.9	17
107	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. Clinical Breast Cancer, 2015, 15, 512-518.	2.4	9
108	Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer, 2015, 15, 138.	2.6	119

#	Article	IF	CITATIONS
109	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. Clinical Breast Cancer, 2015, 15, e197-e204.	2.4	6
110	Comparison of prognosis and specific features according to tumor size in small-sized breast cancer with extensive lymph node involvement Journal of Clinical Oncology, 2015, 33, 81-81.	1.6	3
111	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget, 2015, 6, 43731-43742.	1.8	63
112	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment, 2015, 47, 765-773.	3.0	4
113	Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinomaln Situ. Journal of Breast Cancer, 2014, 17, 83.	1.9	5
114	Comparison of Sentinel Lymph Node Biopsy Guided by the Multimodal Method of Indocyanine Green Fluorescence, Radioisotope, and Blue Dye Versus the Radioisotope Method in Breast Cancer: A Randomized Controlled Trial. Annals of Surgical Oncology, 2014, 21, 1254-1259.	1.5	62
115	Invasive Paget disease of the breast: 20 years of experience at a single institution. Human Pathology, 2014, 45, 2480-2487.	2.0	22
116	Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy?. Breast, 2014, 23, 670-675.	2.2	12
117	Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells. Oncology Reports, 2014, 31, 1423-1428.	2.6	8
118	Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. Oncology Reports, 2014, 32, 2666-2672.	2.6	25
119	Surgical Approach of the Rare Benign Adrenal Tumor. The Korean Journal of Endocrine Surgery, 2014, 14, 228.	0.1	0
120	Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma <i>In Situ</i> . Journal of Breast Cancer, 2013, 16, 404.	1.9	27
121	Poor Outcome of Hormone Receptor–Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea—A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2007, 25, 2360-2368.	1.6	217